Biotech News

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT)4D Molecular Therapeutics, Inc.Company update

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on November 10, 2026, the compensation committee of the Company’s board of directors granted one new non-executive employee 21,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Related news

4D Molecular Therapeutics, Inc.

Genetic Medicines Company 4D Molecular Therapeutics develops genetic medicines using an engineered AAV vector platform known as Therapeutic Vector Evolution. The technology is designed to select vectors for specific tissues and routes of administration rather than relying only on naturally occurring viral capsids. 4D-150 Retinal...

Recent company news

Stock data

Close
10.72 USD
Market cap
484.6M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States